PodcastsSaúde e fitnessBarbell Medicine Podcast

Barbell Medicine Podcast

Barbell Medicine
Barbell Medicine Podcast
Último episódio

426 episódios

  • Barbell Medicine Podcast

    Medical Mystery: The Man Who Got Weaker When He Started Training

    07/04/2026 | 1h 15min
    A 43-year-old man starts exercising and ends up in the ER with a CK over 100x the upper limit of normal. His doctor says it’s from training. We don’t think so. In this episode, Dr. Jordan Feigenbaum and Dr. Austin Baraki walk through the full case — history, labs, diagnosis, and what actually went wrong — then break down the mechanisms behind the answer, the nocebo research, and what the brand-new 2026 guidelines mean for the 40 million Americans on a drug class you’ve definitely heard of.

    We also cover the STOMP trial (do statins actually impair strength gains?), the SAMSON trial (how much of statin intolerance is nocebo?), the difference between myalgia, myositis, and rhabdomyolysis, Austin’s clinical approach to a patient whose strength is declining on a statin, and the treatment escalation pathway for statin-intolerant patients including bempedoic acid, PCSK9 inhibitors, and inclisiran. Plus, where GLP-1 receptor agonists like tirzepatide fit into the cardiovascular risk picture.
    Timestamps
    0:00 — A 43-year-old man is getting weaker, not stronger
    2:09 — Taking the history: Medications, lifestyle, and red flags
    12:53 — The labs come back: CK at 18,979
    16:05 — Metabolic syndrome and the modern treatment approach
    23:15 — Rhabdomyolysis: What it is and why it’s dangerous
    29:50 — Final diagnosis and what went wrong with the medications
    37:15 — 2026 ACC lipid guidelines: What changed
    40:32 — Three mechanisms: How statins affect muscle
    47:02 — The nocebo effect and the SAMSON trial
    54:17 — Do statins impair training? The STOMP trial
    1:00:30 — Who’s at highest risk for statin muscle problems
    1:07:36 — What happened to the patient and options if this is you
    1:14:12 — Five takeaways

    Five Takeaway
     Statin myopathy is real but relatively uncommon. The excess symptom rate above placebo is roughly 1–5% in controlled trials. But in exercising patients, especially on combination therapy, the risk can be higher.
    There are three proposed mechanisms: reduced energy production from CoQ10 depletion, compromised muscle cell membranes from isoprenoid loss, and accelerated protein breakdown from calcium leak via the ryanodine receptor. Exercise amplifies all three, but the vast majority of people compensate.
    If you’re on a statin and your strength is going down, talk to your doctor before stopping the medication or changing your training. A CK test can help separate a drug problem from a programming problem
    The 2026 ACC guidelines list vigorous exercise as a risk factor for statin-associated muscle symptoms for the first time. They also provide statin-intolerant patients a clear escalation pathway: bempedoic acid, ezetimibe, PCSK9 inhibitors, and more.
    Lower is better for LDL. There’s a 33% relative reduction in cardiovascular events at <55 vs. 70 mg/dL. Lower for longer. Healthy lifestyle changes plus effective lipid-lowering therapy are among the best things you can do for cardiovascular risk.

    Next Steps
    For evidence-based resistance training programs: barbellmedicine.com/training-programs
    For individualized training consultation: barbellmedicine.com/coaching
    Explore our full library of articles on health and performance: barbellmedicine.com/resources
    To consult with Drs. Baraki or Feigenbaum email us at [email protected]
    To support us and get ad free listening, plus special product discounts, and exclusive content, go to supercast.barbellmedicine.com

     Resources
    Training Plateau Action Plan (free):
    https://www.barbellmedicine.com/training-plateau-action-plan/
    Fish oil episode:
    https://open.spotify.com/episode/4kRtXZBMZWKkZPDdIKpu1S
    Lp(a): https://www.barbellmedicine.com/blog/lipoprotein-a-testing-and-treatment/

    Guidelines
    Blumenthal RS, Morris PB, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423

    Case
    László A, et al. Exercise and Statin-Fibrate Combination Therapy-Caused Myopathy. BMC Research Notes. 2013;6:52. https://pubmed.ncbi.nlm.nih.gov/23388500/
     
    LDL Targets
    Lee YJ, et al. (Ez-PAVE) Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. NEJM. 2026. PMID: 41910315

    Mechanisms of Statin Myopathy
    Meador BM, Huey KA. Statin-Associated Myopathy and Its Exacerbation with Exercise. Muscle Nerve. 2010;42(4):469–479. https://pubmed.ncbi.nlm.nih.gov/20878737/

    Safitri N, et al. Statin-Induced Rhabdomyolysis: Mechanisms, Risk Factors, Management. Drug Healthc Patient Saf. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8593596/

    Molinarolo S, et al. Cryo-electron microscopy reveals sequential binding and activation of Ryanodine Receptors by statin triplets. Nat Commun. 2025;16(1):11508. doi:10.1038/s41467-025-66522-0

    Thompson PD, et al. Lovastatin Increases Exercise-Induced Skeletal Muscle Injury. Metabolism. 1997;46(10):1206–1210

    Nocebo Effect and Statin Intolerance
    Wood FA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects (SAMSON). NEJM. 2020;383(22):2182–2184. https://pmc.ncbi.nlm.nih.gov/articles/PMC8453640/

    Khan S, et al. Does Googling Lead to Statin Intolerance? Int J Cardiol. 2018;262:25–27. https://pubmed.ncbi.nlm.nih.gov/29706390/

    Gupta A, et al. Adverse Events Associated with Unblinded, but Not with Blinded, Statin Therapy in the ASCOT-LLA. Lancet. 2017;389(10088):2473–2481. https://pubmed.ncbi.nlm.nih.gov/28476288/

    Moon JC, et al. Examining the Nocebo Effect of Statins through the FDA AERS. Circ Cardiovasc Qual Outcomes. 2021;14(1):e007480. https://pubmed.ncbi.nlm.nih.gov/33161769

    Statins and Exercise Outcomes
    Parker BA, et al. Effect of Statins on Skeletal Muscle Function (STOMP). Circulation. 2013;127(1):96–103. https://pubmed.ncbi.nlm.nih.gov/23183941/

    Parker BA, Thompson PD. Effect of Statins on Skeletal Muscle: Exercise, Myopathy, and Muscle Outcomes. Exerc Sport Sci Rev. 2012;40(4):188–194. https://pmc.ncbi.nlm.nih.gov/articles/PMC3463373/

    Mikus CR, et al. Simvastatin Impairs Exercise Training Adaptations. JACC. 2013;62(8):709–714. https://pubmed.ncbi.nlm.nih.gov/23583255/

    Slade JM, et al. The Impact of Statin Therapy and Aerobic Exercise Training. Am Heart J Plus. 2021;10:100028. https://pmc.ncbi.nlm.nih.gov/articles/PMC8477381/

    Gui Y, et al. Efficacy and Safety of Statins and Exercise Combination Therapy. Eur J Prev Cardiol. 2017;24(9):907–916. DOI: 10.1177/2047487317691874 

    Genetic Susceptibility
    SEARCH Collaborative Group. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. NEJM. 2008;359(8):789–799

    Autoimmune Myopathy
    Barkhordarian M, et al. Statin-Induced Autoimmune Myopathy. Am J Case Rep. 2024;25:e944261. https://pubmed.ncbi.nlm.nih.gov/39219126/

    Statin-Fibrate Interactions
    Jones PH, Davidson MH. Reporting Rate of Rhabdomyolysis with Fenofibrate + Statin vs Gemfibrozil + Any Statin. Am J Cardiol. 2005;95(1):120–122

    Bruckert E, et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy (PRIMO Study). Cardiovasc Drugs Ther. 2005;19(6):403–414

    Sinzinger H, O’Grady J. Professional Athletes Suffering from Familial Hypercholesterolaemia Rarely Tolerate Statin Treatment. Br J Clin Pharmacol. 2004;57(4):525–528

    Tirzepatide and GLP-1 Agonists
    Al-kuraishy HM, et al. The mechanistic role of tirzepatide in atherosclerosis. Int J Biol Macromol. 2025;329(1). https://doi.org/10.1016/j.ijbiomac.2025.147734

    Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11704219/

    Hamidi H, et al. Effect of tirzepatide on coronary atherosclerosis progression (T-Plaque trial design). Am Heart J. 2024;278:24–32. doi:10.1016/j.ahj.2024.08.015

    Fish Oil and Omega-3 Fatty Acids
    Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl (REDUCE-IT). NEJM. 2019;380:11–22. https://pubmed.ncbi.nlm.nih.gov/30415628/

    Abdelhamid AS, et al. Omega-3 Fatty Acids for Prevention of Cardiovascular Disease. Cochrane Database Syst Rev. 2020. https://pubmed.ncbi.nlm.nih.gov/32114706/

    Manson JE, et al. Marine n-3 Fatty Acids and Prevention of CVD and Cancer (VITAL). NEJM. 2019;380:23–32. https://pubmed.ncbi.nlm.nih.gov/30415637/
     

    Myopathy Classification
    Selva-O’Callaghan A, et al. Statin-Induced Myalgia and Myositis: Pathogenesis and Clinical Recommendations. Expert Rev Clin Immunol. 2018;14(3):215–224. https://pmc.ncbi.nlm.nih.gov/articles/PMC6019601/

    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
  • Barbell Medicine Podcast

    Overtraining Syndrome: Causes, Diagnosis, and What's Actually Going On

    31/03/2026 | 1h 36min
    In 2022, researchers conducted the most rigorous systematic review ever performed on overtraining syndrome — looking specifically for controlled studies that documented a human transitioning from a healthy training state to an overtrained state. Zero studies met those criteria.
     
    The word "overtrained" appears in coaching certifications, wearable device dashboards, and clinical sports medicine guidelines — and in each context it means something different. That definitional chaos has consequences: it delays real diagnoses, produces nocebo effects with measurable physiological outcomes, and leads athletes to reduce training they didn't need to reduce.

    In this episode, Drs. Jordan Feigenbaum and Austin Baraki work through the full evidence base on overtraining syndrome — the taxonomy, the attempted studies, the six competing mechanistic theories, the biomarker failures, and what's actually happening when a lifter can't make progress.
     
    Timestamps:

    0:00 Cold open — the zero-studies finding
    1:21 Why "overtrained" does four different jobs simultaneously
    16:10 The FOR / NFOR / OTS taxonomy
    19:43 The supercompensation model — borrowed from endurance, never validated for resistance training
    32:28 Austin's clinical differential for fatigue and declining performance
    36:17 RT evidence — what happens when researchers try to induce OTS through lifting
    43:19 Austin — what actually drives the complaints he sees in practice
    47:30 Six theories for what causes overtraining syndrome
    1:01:09 The biomarker problem — why the T:C ratio and cortisol don't work
    1:05:09 What your wearable is actually measuring (and what it isn't)
    1:09:28 Austin — testosterone levels in trained athletes and when to act
    1:13:40 Heart rate variability — limitations for strength training
    1:15:36 Session RPE — the monitoring tool that actually works
    1:17:31 How common is overtraining syndrome, really?
    1:23:04 Three failure modes — what's actually happening when lifters say they feel overtrained
    1:32:14 Austin — what a proper medical workup looks like
    1:34:22 Outro

    What we cover:

    The definition problem — why a single word is doing four incompatible jobs simultaneously, and why that matters clinically and practically.
    The taxonomy — functional overreaching, nonfunctional overreaching, and overtraining syndrome as points on a continuous variable that can only be identified after the fact, not at presentation.
    The supercompensation model — where it came from, why it fails to describe how resistance training adaptation actually works, and how applying it too literally produces both overloading and underloading errors at the same time.
    Austin's clinical differential — what a physician actually works through when a patient presents with fatigue and declining performance, and where overtraining syndrome actually sits on that list.
    What resistance training research shows — including 140 maximal singles, 90 working sets per week, and daily 1-rep max attempts. No study has cleanly induced overtraining syndrome through resistance training. The hormonal data went in the opposite direction from what the endurance overtraining model predicts.
    Six mechanistic theories — glycogen depletion, serotonin/BCAA, autonomic imbalance, central governor, HPA axis dysregulation, and Armstrong's complex systems framework. Each one is partially supported and each falls short.
    The biomarker problem — resting cortisol is normal in 75%+ of OTS cases, the testosterone to cortisol ratio has never been validated against clinical outcomes as an individual diagnostic, and HRV recovery in strength training lags physical recovery by up to 30 hours.
    Austin on wearables — including a clinical pattern he's seeing with GLP-1 receptor agonists: wearable scores indicating deterioration when the clinical picture is actually fine.
    Session RPE as the real tool — why session RPE trending upward at stable training load is a more reliable signal of load-recovery mismatch than any biomarker currently used.
    Prevalence and confounders — the 60% figure, why it almost certainly captures all three FOR/NFOR/OTS categories plus REDS, depression, and illness, and why the residual true training-load-induced OTS in an otherwise healthy athlete may be vanishingly rare.
    Three failure modes — the three things Jordan actually sees in practice when lifters present saying they feel overtrained, and how to distinguish between them using session RPE.
    The medical workup — Austin's practical walkthrough of what to assess when programming and lifestyle changes don't move the needle, including iron deficiency (ferritin testing caveats, lab reference range problems), sleep apnea, post-viral syndromes, and hormone panels done correctly.

    Next Steps:

    For evidence-based resistance training programs: barbellmedicine.com/training-programs

    For individualized training consultation: barbellmedicine.com/coaching

    Explore our full library of articles on health and performance: barbellmedicine.com/resources

    To consult with Drs. Baraki or Feigenbaum email us at [email protected]

    For ad free listening and exclusive discounts, become a Barbell Medicine Plus subscriber at https://barbellmedicine.supercast.com/

     Resources
     
    Taxonomy / Definitions
    Meeusen et al. (2013)
    European College of Sport Science / ACSM consensus statement on FOR, NFOR, and OTS taxonomy. Defines OTS as a diagnosis of exclusion.
    https://pubmed.ncbi.nlm.nih.gov/23247672/

    Meeusen et al. (2006)
    "Often only after a period of complete rest" — the retrospective nature of distinguishing NFOR from OTS.
    https://pubmed.ncbi.nlm.nih.gov/23016079/

    Nocebo Effects in Sport
    2024 Systematic Review
    Nocebo effects in sport were approximately twice the magnitude of placebo effects on performance across 20 studies.
    https://pubmed.ncbi.nlm.nih.gov/38999724/

    Stress-Recovery-Adaptation Model
    Original general adaptation syndrome / stress physiology work in Nature. Foundational source the SRA model was derived from — not a sports science paper.
    https://www.nature.com/articles/138032a0

    Multi-system adaptation timescales; critique of single-wave supercompensation model.
    https://pubmed.ncbi.nlm.nih.gov/3057313/

    Multi-system adaptation timescales; further critique of the SRA "window of opportunity" model.
    https://pubmed.ncbi.nlm.nih.gov/15044685/

    Lack of empirical support for the supercompensation "window of opportunity" in real training scenarios.
    https://pubmed.ncbi.nlm.nih.gov/29189930/

    Resistance Training and OTS
    Grandou et al. (2020)
    Systematic review: 22 studies on resistance training overtraining. 10 showed zero performance decline under deliberate overload. No reliable biomarker established for RT overtraining; sustained performance drop is the only consistent signal.
    https://pubmed.ncbi.nlm.nih.gov/31313309/

    Coleman et al. (2024)
    9-week supervised high-volume RT protocol (~90 sets/week). No OTS criteria met. Ceiling for resistance training-induced OTS is considerably higher than commonly implied.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC10809978/

    Zourdos et al. (2016)
    Case series: 3 competitive strength athletes performed daily 1RM squat for 30 consecutive days. All three improved.
    https://pubmed.ncbi.nlm.nih.gov/26816276/

    Daily 1RM Bench Press Study
    7 athletes attempted a true 1RM bench press every day for 38 days. All improved despite day-to-day fluctuation.
    https://www.thefreelibrary.com/Efficacy+of+Daily+One-Repetition+Maximum+Bench+Press+Training+in...-a0828317501

    3 weeks of daily loading; volume arm hypertrophied. Daily frequency did not produce overtraining; volume drives hypertrophy, not frequency alone.
    https://pubmed.ncbi.nlm.nih.gov/27875635/

    Fry et al. (1994) — Overreaching Protocol
    Original resistance overreaching induction: 10×1 at 100% 1RM daily for 14 days. 1RM dropped ~12 kg. Hormonal response was opposite to endurance OTS profile (cortisol decreased, testosterone slightly increased).
    https://pubmed.ncbi.nlm.nih.gov/7808252/

    Fry et al. (1994) — Endurance Biomarkers
    Endurance OTS biomarkers (T:C ratio) do not apply to high-intensity resistance training overreaching.
    https://pubmed.ncbi.nlm.nih.gov/9843563/

    Fry et al. (2006)
    Same overreaching protocol with muscle biopsies. Beta-2 adrenergic receptor density in vastus lateralis decreased 37%. Orthopedic ceiling hypothesis: structural limits intervene before neuroendocrine axis fully desensitizes.
    https://pubmed.ncbi.nlm.nih.gov/16888042/

    Raastad et al. (2001)
    Daily submaximal leg training for 2 weeks; 1RM increased 6%. Intensity (not frequency) is the necessary ingredient for overreaching in resistance training.
    https://pubmed.ncbi.nlm.nih.gov/11394254/

    Margonis et al. (2007)
    12-week progressive RT peaking at ~14 tonnes/week. Significant 1RM decrements not restored after 6-week taper — the only resistance training study to approach true OTS criteria.
    https://pubmed.ncbi.nlm.nih.gov/17697935/

    HPA Axis / Biomarkers

    Cadegiani & Kater (2017) — EROS Study
    Resting cortisol is normal in ≥75% of OTS studies. Reduced pituitary ACTH output (not adrenal failure) is the upstream dysregulation in OTS. "Adrenal fatigue" is mechanistically backwards.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5722782/

    EROS Study — Extended Findings
    Further EROS study data on HPA axis dysregulation patterns in OTS.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6590962/

    Testosterone: acute 30% drops occur routinely after a marathon and normalize within days. Never validated as an individual OTS diagnostic.
    https://pubmed.ncbi.nlm.nih.gov/3744643/

    Saw et al. (2016)
    56-study systematic review of athlete monitoring tools. Subjective measures (mood, perceived fatigue, sleep quality) tracked training load changes with greater sensitivity than objective markers including hormones, resting HR, and HRV.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4789708/

    Meeusen et al. (2004/2010) — Two-Bout Exercise Protocol
    Two maximal incremental tests 4 hours apart with serial blood draws. OTS athletes show blunted ACTH/prolactin response to second bout; NFOR athletes show exaggerated response. Most validated objective test available; not a field tool.
    https://pubmed.ncbi.nlm.nih.gov/18703548/

    HRV as a Monitoring Tool
    HRV for OTS detection: weak data, foundational work done in cyclists and triathletes only.
    https://pubmed.ncbi.nlm.nih.gov/23852425/

    Strength recovery occurred ~30 hours after heavy loading; HRV had not normalized at 60 hours. Using HRV as a daily training prescription tool in strength athletes is an untested assumption.
    https://pubmed.ncbi.nlm.nih.gov/21273908/

    Session RPE and Monitoring
    Foster et al. (1998)
    Session RPE method: training load quantified as RPE × session duration. Key monitoring metric throughout the episode.
    https://pubmed.ncbi.nlm.nih.gov/9662690/

    Soreness, mood, and motivation relative to training load as monitoring signals.
    https://pubmed.ncbi.nlm.nih.gov/38321325/

    Prevalence
    Morgan et al. (1987)
    The commonly cited 60% OTS prevalence figure. Retrospective self-report using the term "staleness," conducted before the current taxonomy existed. Almost certainly captures all three tiers of the FOR/NFOR/OTS continuum.
    https://pubmed.ncbi.nlm.nih.gov/3676635/

    Confounders: PED Use
    Anonymous Survey Data (2011)
    29% of Track and Field World Championship athletes admitted PED use; 45% at Pan-Arab Games.
    https://core.ac.uk/download/pdf/109992897.pdf

    Lippi et al. (2015)
    WADA detects PED use in only 1–2% of samples; USADA detection rate <1%. Elite athlete PED use is substantially underreported in the OTS literature.
    https://www.nature.com/articles/517529a

    Confounders: Psychiatric Conditions

    Armstrong & VanHeest (2002)
    Overlap between OTS and major depression. Depression can produce every OTS symptom; any OTS workup without a formal depression screen is incomplete.
    https://pubmed.ncbi.nlm.nih.gov/11839081/

    Confounders: Energy Availability

    Cadegiani et al. (2021)
    86% of OTS studies showed co-occurrence of reduced energy availability with OTS-like presentation.
    https://pubmed.ncbi.nlm.nih.gov/34181189/

    Autoregulation and RPE — Part I
    Barbell Medicine blog post on autoregulation and RPE-based programming.
    https://www.barbellmedicine.com/blog/autoregulation-and-rpe-part-i/

    Training Plateau Action Plan
    Barbell Medicine practical guide for diagnosing and addressing training plateaus.
    https://www.barbellmedicine.com/training-plateau-action-plan/

    Injury / Rehab Coaching Questionnaire
    https://www.barbellmedicine.com/coaching-questionnaire-injury-rehab/

    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
  • Barbell Medicine Podcast

    Episode #391: VO2 Max vs. Cardiorespiratory Fitness, GLP-1 Costs, and the 10,000-Step Myth | Direct Line March 2026 (Free)

    24/03/2026 | 30min
    In this free preview of the March 2026 Direct Line AMA. Drs. Feigenbaum and Baraki cover: VO2 max versus cardiorespiratory fitness for longevity (are Peter Attia’s targets evidence-based? — with Goodhart’s Law and the JAMA evidence), what GLP-1 medications actually cost now via manufacturer programs ($149–449/month), and whether 7,000–10,000 daily steps actually meet the bar for cardiovascular training.

    Full episode for Barbell Medicine Plus subscribers at https://barbellmedicine.supercast.com/

    Timestamps:
    0:00 — Introduction
    3:26 — VO2 Max vs. Cardiorespiratory Fitness for Longevity
    14:11 — GLP-1 Costs: What you should actually be paying now
    21:43 — Is Walking Enough for Cardiovascular Health?

    Next Steps:

    For evidence-based resistance training programs: barbellmedicine.com/training-programs

    For individualized training consultation: barbellmedicine.com/coaching

    Explore our full library of articles on health and performance: barbellmedicine.com/resources

    To consult with Drs. Baraki or Feigenbaum email us at [email protected]

    Resources:

    JAMA Network Open — Cardiorespiratory Fitness & Long-term Mortality (Mandsager et al.) — Exercise capacity (METs) and longevity — the foundational CRF/mortality study cited in the episode https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707428
    JAMA — Blair et al. — Physical fitness and all-cause mortality: a prospective study of healthy men and women https://jamanetwork.com/journals/jama/fullarticle/379243
    Barbell Medicine Vital Five — Multi-modal CRF benchmarks and longevity targets https://www.barbellmedicine.com/vital-5-action-plan/
    Lilly Direct — Zepbound (tirzepatide) — Manufacturer direct program ($299–449/month) https://www.lillydirect.com/zepbound
    NovoCare — Wegovy (semaglutide) — Manufacturer savings program ($149–349/month) https://www.novocare.com/patient/medicines/wegovy.html
    Orforglipron — Eli Lilly oral GLP-1 — What to know about orforglipron (small-molecule oral GLP-1 agonist, pending FDA approval) https://www.lilly.com/news/stories/what-to-know-about-orforglipron

    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
  • Barbell Medicine Podcast

    Episode #390: Why Your Waist Matters More Than Your Weight — The Science of Visceral Fat

    17/03/2026 | 44min
    You can have a completely normal BMI and be on your way to cardiovascular disease, type 2 diabetes, and metabolic syndrome without triggering a single alert on a standard health screening. The fat that predicts metabolic risk most accurately isn't the fat your scale or your doctor is tracking. Dr. Jordan Feigenbaum breaks down the science of visceral fat — what it is, how it causes disease, how to measure it correctly at home for free, and what the evidence actually shows about exercise, GLP-1 medications, and testosterone.

    Timestamps:

    00:00:00 Cold Open: The Visceral Fat Finding
    00:00:49 The Scale Problem — What Body Weight Actually Measures
    00:03:50 What Is Visceral Fat — and Why It's Not Just "Belly Fat"
    00:05:04 Three Competing Theories: How Visceral Fat Actually Causes Disease
    00:08:35 Adipokines: PAI-1, Angiotensinogen, and What Happens When Adiponectin Drops
    00:09:52 How to Measure: Three Sites That Don't Give the Same Number
    00:14:30 Clinical Thresholds, Ethnic Adjustments, and the Waist-to-Height Ratio
    00:15:45 The Weight-to-Waist Ratio: Tracking the Quality of Your Fat Loss
    00:19:20 Sleep, Cortisol, and Why the Hormonal Environment Has to Support the Work
    00:21:24 Why Exercise Reduces Visceral Fat 6× More Than Diet Alone
    00:22:02 Mechanism 1 — Beta-3 Adrenergic Receptors and Preferential Visceral Fat Mobilization
    00:24:10 Mechanism 2 — Myokines: The Fat-Burning Signal Only Contracting Muscle Can Send
    00:26:21 GLP-1 Agonists and Body Composition: What the Clinical Trials Actually Show
    00:28:05 DXA's Blind Spot: Myosteatosis, Glycogen, and Why Lean Mass Numbers Are Inflated
    00:30:10 SEMALEAN, the BELIEVE Trial, and the 1-in-10 Reality of Long-Term Lifestyle Programs
    00:33:15 Testosterone, Visceral Fat, and the Aromatase Feed-Forward Loop
    00:36:05 Three Testosterone Ranges: Deficient, Eugonadal, and Supraphysiological
    00:38:05 The Bhasin 4-Group Study — and Why AAS Are a Class, Not a Synonym for TRT
    00:39:33 Tesamorelin: The GHRH Analogue That Selectively Targets Visceral Fat
    00:40:53 Practical Framework: What to Measure, When, and What to Do
    00:43:20 Key Takeaways

    Next Steps

    For evidence-based resistance training programs: barbellmedicine.com/training-programs
    For individualized training consultation: barbellmedicine.com/coaching
    Explore our full library of articles on health and performance: barbellmedicine.com/resources
    To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/
    To consult with Drs. Baraki or Feigenbaum email us at [email protected]
    Barbell Medicine Vital 5 Action Plan: https://www.barbellmedicine.com/vital-5-action-plan/

    Resources:

    https://pubmed.ncbi.nlm.nih.gov/11502820/
    https://pubmed.ncbi.nlm.nih.gov/33567185/
    https://pubmed.ncbi.nlm.nih.gov/35658024/
    https://pubmed.ncbi.nlm.nih.gov/40318682/
    https://pubmed.ncbi.nlm.nih.gov/41068996/
    https://pubmed.ncbi.nlm.nih.gov/41772149/
    https://pubmed.ncbi.nlm.nih.gov/23944298/
    https://pubmed.ncbi.nlm.nih.gov/20948519/
    https://pubmed.ncbi.nlm.nih.gov/27213481/
    https://pubmed.ncbi.nlm.nih.gov/23303913/

    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
  • Barbell Medicine Podcast

    Episode #389: Your Liver Enzymes Are Elevated — But It Might Not Be Your Liver

    09/03/2026 | 1h 1min
    A fit, healthy 39-year-old was nearly sent for a liver biopsy. The cause? Was it that he went to the gym before every blood draw or because his supplement was throwing his labs off?. Dr. Jordan Feigenbaum and Dr. Austin Baraki break down the blind spot that sends thousands of healthy athletes down an expensive, potentially unnecessary diagnostic rabbit hole every year.
    Timestamps:
    00:01:09  Introducing the Case
    00:03:44  How to Read a Liver Panel: ALT, AST, GGT, Alk Phos, Albumin Explained
    00:10:50  What Is GGT and Why Does It Matter Clinically?
    00:16:38  Why Exercise, Protein, and Creatine Aren't on the Differential (Yet)
    00:17:35  The Workup: Hepatitis Panels, Abdominal Ultrasound, and More
    00:19:42  Second Set of Labs — The Mystery Deepens
    00:25:25  Updated Differential: What's Still on the List?
    00:27:08  The Labs Normalize — A Critical Clue Appears
    00:31:40  The Reveal: Exercise Was the Cause All Along
    00:32:18  The Mechanism: How Exercise Elevates 'Liver' Enzymes
    00:32:54  Point 1 — ALT & AST Are Not Exclusively Liver Enzymes
    00:33:49  Point 2 — It's Unavoidable: 100% of Lifters Are Affected
    00:36:02  Point 3 — It Takes 10–12 Days to Normalize
    00:37:00  Point 4 — It's Mostly Harmless
    00:38:27  56% of Physicians Miss This Diagnosis
    00:38:48  Why Clinicians Overlook Exercise History
    00:44:01  Point 5 — GGT as the Differentiator (And Its Limits)
    00:46:42  Why Alkaline Phosphatase Also Rises Post-Workout
    00:48:51  The Cost of Missing Lifestyle Context: Over- and Under-Diagnosis
    00:53:29  What to Say to Your Doctor: 3 Patient Scripts
    00:59:31  5 Key Takeaways
    01:00:25  Final Advice from Dr. Baraki 

    Next Steps
    For evidence-based resistance training programs: barbellmedicine.com/training-programs
    For individualized training consultation: barbellmedicine.com/coaching
    Explore our full library of articles on health and performance: barbellmedicine.com/resources
    To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/
    To consult with Drs. Baraki or Feigenbaum email us at [email protected] 
    Barbell Medicine Vital 5 Action Plan: https://www.barbellmedicine.com/vital-5-action-plan/

    Resources:
    Case: https://pubmed.ncbi.nlm.nih.gov/37025214/
    https://pubmed.ncbi.nlm.nih.gov/29059178/ 
    https://pmc.ncbi.nlm.nih.gov/articles/PMC7438350/
    https://pubmed.ncbi.nlm.nih.gov/18557801/
    https://pubmed.ncbi.nlm.nih.gov/19209234/
    https://pubmed.ncbi.nlm.nih.gov/11476029/
    https://pmc.ncbi.nlm.nih.gov/articles/PMC11165564/
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12460594/ 
    https://pmc.ncbi.nlm.nih.gov/articles/PMC2291230/
    https://pmc.ncbi.nlm.nih.gov/articles/PMC11319523/ 
    https://pmc.ncbi.nlm.nih.gov/articles/PMC3936967/
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12188904/
    https://pmc.ncbi.nlm.nih.gov/articles/PMC7969109/
    https://pmc.ncbi.nlm.nih.gov/articles/PMC11498664/
    https://pmc.ncbi.nlm.nih.gov/articles/PMC3104191/

    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm

    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy

Mais podcasts de Saúde e fitness

Sobre Barbell Medicine Podcast

Podcast by Barbell Medicine
Site de podcast

Ouça Barbell Medicine Podcast, On Purpose with Jay Shetty e muitos outros podcasts de todo o mundo com o aplicativo o radio.net

Obtenha o aplicativo gratuito radio.net

  • Guardar rádios e podcasts favoritos
  • Transmissão via Wi-Fi ou Bluetooth
  • Carplay & Android Audo compatìvel
  • E ainda mais funções
Informação legal
Aplicações
Social
v8.8.7| © 2007-2026 radio.de GmbH
Generated: 4/9/2026 - 10:00:10 PM